S1P/S1PR 

 57 Products   57 Products   190 Diseases   11291 News 


«12...919293949596979899100101...109110»
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  Progressive multifocal leukoencephalopathy after fingolimod treatment. (Pubmed Central) -  Aug 9, 2019   
    The estimated risk was 0.069 per 1,000 patients (95% confidence interval: 0.039-0.114), and the estimated incidence rate was 3.12 per 100,000 patient-years (95% confidence interval: 1.75-5.15). Neither clinical manifestations nor radiographic features suggested any unique features of fingolimod-associated PML.
  • ||||||||||  s-nitrosoglutathione (N30-201) / Alpine
    Journal:  S-Nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis. (Pubmed Central) -  Aug 3, 2019   
    However, neither exogenous GSNO nor N6022 treatment did not cause significant systemic lymphopenic effect as compared to FTY720. Taken together, these data document that optimization of cellular GSNO homeostasis by GSNOR inhibitor (N6022) in NO metabolizing cells attenuates EAE disease via selective inhibition of pro-inflammatory subsets of CD4 cells (T1/T17) while upregulating anti-inflammatory subsets of CD4 cells (T2/Treg) without causing lymphopenic effects and thus offers a potential treatment option for MS/EAE.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Preclinical, Journal:  Differential Tolerance to FTY720-induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of S1P Receptor Adaptation. (Pubmed Central) -  Aug 1, 2019   
    Furthermore, the finding that tolerance develops to antinociception in the tail-flick test but not in chronic neuropathic pain suggests a differential mechanism of FTY720 action between these models. The observation that repeated FTY720 administration led to desensitized S1PR1 signaling throughout the CNS suggests the possibility that S1PR1 activation drives the acute thermal antinociceptive effects, whereas S1PR1 desensitization mediates: 1) tolerance to thermal antinociceptive actions of FTY720; and 2) the persistent anti-allodynic effects of FTY720 in neuropathic pain by producing functional antagonism of pro-nociceptive S1PR1 signaling.
  • ||||||||||  Paxil (paroxetine) / Generic Mfg., Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  S1P receptor phosphorylation, internalization and interaction with Rab proteins: effects of sphingosine 1-phosphate, FTY720-P, phorbol esters and paroxetine. (Pubmed Central) -  Aug 1, 2019   
    The data suggested that the three agents induce interaction with early endosomes, but that the natural agonist induced rapid receptor recycling, whereas activation of protein kinase C favored interaction with late endosome and slow recycling and FTY720-phosphate triggered receptor interaction with vesicles associated with proteasomal/ lysosomal degradation. The ability of bisindolylmaleimide I and paroxetine to block some of these actions suggested the activation of protein kinase C was associated mainly with the action of phorbol myristate acetate, whereas G protein-coupled receptor kinase 2 was involved in the action of the three agents.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Journal, HEOR:  Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in IRAN. (Pubmed Central) -  Aug 1, 2019   
    According to the results of this study, the cost-effectiveness and cost-utility of fingolimod were higher than those of natalizumab. Therefore, it is recommended that treatment with fingolimod be the first priority of second-line treatment for MS patients, and policy-makers and health managers are encouraged to make efforts in order to increase insurance coverage and reduce the out-of-pocket payments of these patients.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  Fingolimod for Irradiation-Induced Neurodegeneration. (Pubmed Central) -  Jul 31, 2019   
    FTY720 treatment of NPCs prior to X-ray exposure and of mice prior to cranial irradiation is neuroprotective. No effects on neurogenesis were found.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  Early onset of fingolimod-associated macular edema (Pubmed Central) -  Jul 26, 2019   
    Regular ophthalmologic check-ups at 4‑week intervals over a period of 3 months are meaningful after beginning fingolimod treatment. As before, it is still a key aspect to determine predictive opthalmologic and neurological factors before beginning treatment to evaluate which patients are at risk of fingolimod-associated macular edema.
  • ||||||||||  Tysabri (natalizumab) / Biogen, FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Journal:  Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. (Pubmed Central) -  Jul 26, 2019   
    The use of high-efficacy therapies with long washout periods before conception was associated with an increased risk of relapses during pregnancy. Postpartum relapse occurrence was similar to that in previous reports.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Observational data, Journal:  Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. (Pubmed Central) -  Jul 24, 2019   
    Disease reactivation was observed in a significant proportion of patients treated with FTY-EOD. Neurologists should be cautious when reducing FTY administration to every other day, especially in younger patients and those previously treated with natalizumab.
  • ||||||||||  simvastatin / generics
    Review, Journal:  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. (Pubmed Central) -  Jul 19, 2019   
    The purpose of this article is to discuss important clinical and pathophysiologic differences between relapsing and progressive forms of MS, review previous notable trials of drugs in progressive MS, examine current literature regarding recent and promising progressive MS treatments, and discuss future considerations for progressive MS therapeutics and management. Specifically, the current evidence regarding treatment of progressive MS with ocrelizumab, simvastatin, ibudilast, alpha-lipoic acid, high-dose biotin, siponimod, and cell-based therapies are discussed.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  Anti-epileptogenic and Anti-convulsive Effects of Fingolimod in Experimental Temporal Lobe Epilepsy. (Pubmed Central) -  Jul 19, 2019   
    Intriguingly, fingolimod exerted robust anti-convulsive activity in kainate-induced SE mice treated in the chronic TLE stage and had neuroprotective and anti-gliotic effects and reduced cytotoxic T cell infiltrates. Finally, the expression profile of fingolimod target-S1PRs in human hippocampal biopsy tissue of pharmacoresistant TLE patients undergoing epilepsy surgery for seizure relief suggests repurposing of fingolimod as novel therapeutic perspective in focal epilepsies.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen
    Clinical, Journal:  Real life use of oral disease modifying treatments in Austria. (Pubmed Central) -  Jul 19, 2019   
    Finally, the expression profile of fingolimod target-S1PRs in human hippocampal biopsy tissue of pharmacoresistant TLE patients undergoing epilepsy surgery for seizure relief suggests repurposing of fingolimod as novel therapeutic perspective in focal epilepsies. In the AMSTR, there was no difference concerning ARR, probability for a relapse, EDSS change, treatment interruption, EDSS progression or regression between oral DMTs, except regarding less sustained EDSS progression for 12 weeks concerning DMF vs fingolimod.
  • ||||||||||  Zeposia (ozanimod) / BMS
    Trial completion:  Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response (clinicaltrials.gov) -  Jul 18, 2019   
    P1,  N=92, Completed, 
    In the AMSTR, there was no difference concerning ARR, probability for a relapse, EDSS change, treatment interruption, EDSS progression or regression between oral DMTs, except regarding less sustained EDSS progression for 12 weeks concerning DMF vs fingolimod. Recruiting --> Completed
  • ||||||||||  Zeposia (ozanimod) / BMS
    Trial completion date, Trial primary completion date:  An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) -  Jul 10, 2019   
    P3,  N=890, Recruiting, 
    Our data suggest PGLYRP4 functions, in part, by preventing TCT induced airway damage. Trial completion date: Mar 2022 --> Dec 2021 | Trial primary completion date: Mar 2022 --> Dec 2021
  • ||||||||||  FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  DHHC5-mediated palmitoylation of S1P receptor subtype 1 determines G-protein coupling. (Pubmed Central) -  Jul 5, 2019   
    This indicates that FTY720-P switches off the S1P signal in PM, while switching on its signal continuously inside the cells. We propose that DHHC5-mediated palmitoylation of S1P1R determines Gi coupling and its signalling in a spatio/temporal manner.
  • ||||||||||  BXQ-350 / Bexion
    Enrollment closed, Trial primary completion date, Metastases:  Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jul 5, 2019   
    P1,  N=86, Active, not recruiting, 
    We propose that DHHC5-mediated palmitoylation of S1P1R determines Gi coupling and its signalling in a spatio/temporal manner. Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2019 --> Jun 2019
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Retrospective data, Review, Journal, Real-World Evidence:  Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis. (Pubmed Central) -  Jul 4, 2019   
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2019 --> Jun 2019 Across heterogeneous study designs and patient populations found in real-world studies, the consensus 1-year fingolimod persistence rate exceeded 80%, consistent with persistence rates identified in the recently-completed trial, PREFERMS.
  • ||||||||||  Tysabri (natalizumab) / Biogen, FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Clinical, Journal:  Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. (Pubmed Central) -  Jun 30, 2019   
    Across heterogeneous study designs and patient populations found in real-world studies, the consensus 1-year fingolimod persistence rate exceeded 80%, consistent with persistence rates identified in the recently-completed trial, PREFERMS. Knowledge of post-DMT relapse and disability progression rates and predictors of post-DMT disease activity allows for a more informed discussion of DMT discontinuation in those patients who are considering this option.
  • ||||||||||  FTY720, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe
    Journal:  S1P1 deletion differentially affects TH17 and Regulatory T cells. (Pubmed Central) -  Jun 28, 2019   
    Importantly, our study revealed that S1P1 not only regulated the egress of Treg cells out of lymphoid organs and subsequent non-lymphoid tissue distribution but also their phenotypic diversity. Most of the Treg cells found in S1P1-deficient mice as well as MS patients on fingolimod therapy had an activated phenotype and were more prone to apoptosis, thus converted to effector Treg. Our results provide novel insight into the functions of S1P1 and potential impact of long term fingolimod use on Th17 and Treg cell biology and general health in MS patients.